Diplomat Pharmacy (DPLO) Tops Q3 EPS by 10c; Lifts FY15 Outlook

Diplomat Pharmacy (NYSE: DPLO) reported Q3 EPS of $0.26, $0.10 better than the analyst estimate of $0.16. Revenue for the quarter came in at $947 million versus the consensus estimate of $926.41 million.

Diplomat Pharmacy sees FY2015 EPS of $0.69-$0.73, versus prior guidance of $0.56-$0.60 and the consensus of $0.59. Diplomat Pharmacy sees FY2015 revenue of $3.25-3.40 billion, versus prior guidance of $3.20-3.40 billion and the consensus of $3.31 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Kodiak Gas Services, Inc. (KGS) Reports Q2 EPS of $0.55
• Nelnet (NNI) Misses Q2 EPS by 36c
• Zentalis Pharmaceuticals, Inc. (ZNTL) Misses Q2 EPS by 11c